Inhibikase shares surge 36.34% premarket after strategic shift to IkT-001Pro for pulmonary hypertension amid Parkinson’s program pause.

Inhibikase Therapeutics surged 36.34% in premarket trading following a strategic realignment prioritizing its IkT-001Pro candidate for pulmonary arterial hypertension (PAH). The company paused development of its Parkinson’s drug, Risvodetinib, after it failed to meet primary endpoints in Phase 2, shifting resources to the PAH program. Investors reacted positively to the decision, as it reduces exposure to high-risk neurodegenerative research and focuses on a more viable therapeutic area. The announcement of a planned global Phase 3 trial, "IMPROVE-PAH," set to begin in Q1 2026, further bolstered confidence. Additionally, the firm’s late-2024 private placement provided dedicated funding for IkT-001Pro development, reinforcing operational readiness. The sharp premarket gain reflects optimism about the strategic pivot and the potential for near-term clinical progress in PAH.